Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of
How this was made
The 30-second read
Why it matters
The report provides the first public financial numbers for Q3 2026 and updates on two key clinical programs, offering fresh data for traders.
Market read
Primary disclosure of earnings and pipeline milestones for a micro‑cap biotech; modest trading relevance.
What to watch
Potential funding needs and IND clearance risk for TTI-109 could constrain near‑term execution.
Background
The filing is a standard SEC Form 8‑K reporting quarterly results for Tvardi Therapeutics, a clinical‑stage biotech focused on STAT3 inhibition.
Ticker impact
TVRD disclosed Q3 2026 results with a net loss of $6.1M, cash of $22.3M and progress on its TTI-109 ulcerative colitis program and TTI-101 hepatocellular carcinoma trial.
likely modest downside as investors price the loss and cash position
Losses are larger than prior year but cash is sufficient to Q3 2027; clinical milestones drive future upside.
Market effects
Biotech sector may see modest pressure as a microcap reports a loss, but the clinical updates could spark interest in STAT3‑targeted therapies.
Limited to US biotech investors; no broader regional effect.
Low global impact; relevance confined to investors tracking early‑stage biotech pipelines.
Counterpoint
Despite the loss, the cash runway and upcoming trial readouts could make the stock a long‑term upside play.
Key entities
- CompanyTvardi Therapeutics
Clinical‑stage biopharma developing STAT3 inhibitors.
- ExecutiveImran Alibhai
CEO of Tvardi Therapeutics, quoted on program progress.

